Reuters: Panic in the private credit market spreads to Wall Street, with multiple banks and funds restricting redemptions
Odaily reported that as investors' concerns about private credit risk rise, several Wall Street giants and private credit funds are taking measures to address potential pressures. Some US banks are tightening loans to private credit, while funds are restricting investor redemptions. According to Moody’s data, by June 2025, US banks will have provided nearly $300 billions in loans to private credit, another $285 billions to private equity funds, with unused credit lines reaching $340 billions. Market concerns stem from issues of valuation and transparency, as well as private credit exposure risks revealed in bankruptcy cases such as First Brands and Tricolor. Analysts point out that investors remain doubtful about exposure to software and technology assets, and with liquidity tightening, the private credit market may remain under pressure in the short term. The main actions taken by Wall Street giants and private credit funds include:
1. JPMorgan Chase has marked down the valuation of some private credit loans related to the software sector, reducing further lending.
2. Morgan Stanley has restricted redemptions from the North Haven Private Income Fund, fulfilling only about 45.8% of investor requests in the first quarter to avoid market mismatch.
3. BlackRock imposed a 5% redemption cap on the HPS Corporate Lending Fund, with $1.2 billions in redemption requests in the first quarter, but only $620 millions were paid out.
4. Blackstone’s BCRED fund saw net redemptions of $1.7 billions in the first quarter, with employees injecting $400 millions to fill the gap, and raised the quarterly redemption cap from 5% to 7%.
5. Blue Owl Capital sold $1.4 billions in assets to repay investors and permanently halted redemptions for one fund.
6. Cliffwater limited the fund’s quarterly redemption ratio to 7% to address about 14% of investor redemption requests in the first quarter. (Reuters)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Forex Today: US flash Consumer Sentiment and Canadian jobs in the limelight
Malaysian Ringgit: Fiscal anchor case – MUFG
Nasdaq Drops Over 300 Points After OpenAI's Revenue Comes In $20 Billion Short
BUZZ-Revolution Medicines stock drops due to concerns over pancreatic cancer drug data
On October 8, Revolution Medicines (RVMD.O) shares fell 8.1% in afternoon trading to $185.91. RBC Capital Markets stated that the share price decline appeared to be driven by the latest U.S. Food and Drug Administration (FDA) review documents regarding the company's pancreatic cancer drug Rasonque, particularly the disclosure of objective response rate data for specific RAS mutation subgroups. RBC pointed out that overall survival, rather than objective response rate, is a more meaningful indicator of efficacy, and that the sell-off overlooked Rasonque's broad activity across a variety of RAS mutation subgroups. RBC stated: "While we acknowledge that today's share price decline takes place against the backdrop of overall weakness in the biotech sector, we still believe that the market's reaction to the FDA review documents is an overreaction, given that the drug was approved on the basis of highly clinically meaningful efficacy and has received positive feedback from physicians." Including intraday fluctuations, the stock has more than doubled year-to-date. (Note: For the convenience of non-English speakers, Reuters has automatically translated its reports into several other languages. Automated translations may be inaccurate or lack necessary context; Reuters does not guarantee the accuracy of these automated translations and provides them only for reader convenience. Reuters does not accept liability for any damage or loss arising from the use of automated translation features.)
